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Abstract
Background: Progressive supranuclear palsy (PSP) and parkinsonian variant of multiple system atrophy (MSA-P) are
clinically difficult to differentiate from idiopathic Parkinson’s disease (PD), particularly in the early stages of the
disease. Previous reports indicated that the olfactory function is relatively intact or slightly reduced in patients with
PSP and MSA-P, suggesting that the odor stick identification test for Japanese (OSIT-J), which is a short and simple
noninvasive test that is potentially useful clinically for detecting early-stage PD in Japan, may be useful in the
differential diagnosis of early-stage PD from MSA-P and PSP. There is no information on the sensitivity and
specificity of OSIT-J in the diagnosis of parkinsonian syndromes such as PSP and MSA-P.
Methods: We assessed the olfactory function using the OSIT-J test in 94 Japanese patients with idiopathic PD, 15
with MSA-P, 7 with PSP, and 29 age-matched control subjects.
Results: The mean ± SD score of OSIT-J in patients with PD (4.4 ± 2.9) was significantly lower than in patients with
MSA-P (8.7 ± 2.2, P < 0.0001), PSP (7.6 ± 2.2, P < 0.0057), and control subjects (10.5 ± 1.3, P < 0.0001). The area
under the curve (AUC) of receiver operating characteristic (ROC) to discriminate PD from normal control using
OSIT-J scores was 0.97 (95% confidence interval, 0.95-1.00), from MSA-P 0.87 (0.80-0.95), and from PSP 0.81 (0.66-
0.96).
Conclusion: The OSIT-J is a potentially useful clinical test not only for detection of olfactory deficit in PD but also
for differentiating PD from MSA-P and PSP.
Background
Olfactory dysfunction is recognized as a non-motor
symptom in idiopathic Parkinson’s disease (PD), and is a
maker for preclinical diagnosis of PD based on the
appearance of pathological changes in the olfactory sys-
tem before the development of motor symptoms [1]. A
recent study indicated that the early appearance of
impaired olfaction prior to other clinical features of PD
could be a useful screening tool to detect those at high
risk for the development of PD in later life [2]. In fact,
several Japanese researchers employ the 12-odorant test,
the Odor Stick Identification Test for Japanese (OSIT-J)
in the clinical testing of PD [3-5] and have reported
their findings of dysosmia and that it did not correlate
with motor function, disease duration, or medication,
indicating that OSIT-J scores are independent of all
other measures in PD [3,4]. In addition to the practice
in Japan, the results of the University of Pennsylvania 12
smell identification test (UPSIT), which is also a smell
identification test [6-8], in d i c a t et h a tO S I T - Ji sas h o r t
and simple noninvasive test that is potentially useful
clinically for detecting early-stage PD.
The diagnosis of PD is based on clinical criteria, the
accuracy of such diagnosis even in patients with chronic
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palsy (PSP) and parkinsonian variant of multiple system
atrophy (MSA-P) are neurodegenerative disorders that
are clinically difficult to differentiate from idiopathic
PD, particularly in the early stages of the disease, when
the typical clinical signs are not clearly evident [10]. Pre-
vious reports indicated that the olfactory function is
relatively intact or slightly reduced in patients with PSP
and MSA-P [11-15], suggesting that OSIT-J may be use-
ful in the differential diagnosis of early-stage PD from
MSA-P and PSP [15,16]. To our knowledge, there is no
information on the sensitivity and specificity of OSIT-J
in the diagnosis of parkinsonian syndromes such as PSP
and MSA-P. The aim of the present study was to evalu-
ate the OSIT-J in patients with idiopathic PD, MSA-P,
and PSP.
Methods
Patients and Control Subjects
From October 2008 through March 2011, consecutive
nondemented patients underwent OSIT-J as part of the
initial clinical evaluation of parkinsonism, either as inpa-
tients or outpatients at the Department of Neurology,
The Jikei University Aoto Hospital. The clinical diagno-
sis of PD, MSA-P, PSP was determined by three authors
(MS, MY, MH, with more than 10-year experience in
movement disorders) according to established consensus
criteria. The patients were included in the study only if
they fulfilled the criteria for PD [17], MSA-P [18], and
PSP [19]. The controls were partners of the patients or
subjects with normal neurological examination free of
central nervous system (CNS) diseases. Seven patients
with PSP (4 men, mean age 70.6 years, mean disease
duration 2.4 years), 15 patients with MSA-P (9 men,
67.3 years, 2.1 years), 94 patients with PD (47 men, 68.6
years, 5.1 years) and 29 age-matched healthy subjects (9
men, 66.1 years) were included in this study. All patients
were evaluated using the Unified Parkinson’sD i s e a s e
Rating Scale (UPDRS) [20] and Hoehn and Yahr (HY)
stage [21] for estimation of disease severity. We
excluded patients with Mini Mental State Examination
(MMSE) score of less than 24, because it was unlikely
that they could adequately comprehend and respond to
the odor. The following patients were also excluded
from the study: patients with 1) history of stroke (PD; n
= 1), epilepsy (PD; n = 1), or psychiatric illness (PD; n =
1), 2) missing clinical data (PD; n = 3, MSA-P; n = 1),
and 3) obvious medical complications that could lower
the accuracy of clinical diagnosis of PD (n = 3). Two
cases with autosomal recessive juvenile parkinsonism
[22] was also excluded. The enrolled subjects were free
from other conditions that can affect olfactory function
such as smoking, usage of certain medications, history
of nasal surgery, pulmonary disease, hormonal disorders,
perennial allergies, or abuse of drugs or alcohol.
Informed consent was obtained from all participants
following a full explanation of the study. As stated in
the Introduction, the OSIT-J test is used routinely in
clinical practice in Japan and in our hospital. Accord-
ingly, we explained to all participants that the collected
clinical data could be used in the future for research
purpose but all results will be anonymous. The study
was approved by the ethics committee of Jikei university.
Odor Stick Identification Test for Japanese (OSIT-J)
OSIT-J (Daiichi Yakuhin, Co., Tokyo, Japan) comprises
12 different odorants familiar to the Japanese population
[23,24]: rose, condensed milk, Japanese orange, curry,
roasted garlic, fermented beans/sweaty socks, cooking
gas, menthol, India ink, wood, and Japanese cypress
(hinoki) [3,4]. These odors were chosen from clusters
representing Japanese daily life and are familiar to the
Japanese population, and each odorant was selected
from the essential oils, pure chemicals, or mixed odor-
ants produced by Takasago International Corporation
(Tokyo). For each odorant, the subject is presented with
a card showing four names of odors and is asked to
select the odor presented. The total number of correct
a n s w e r sf o rt h e1 2o d o r a n t sp r e s e n t e di st h eO S I T - J
score [3]. Thus, the score of the OSIT-J ranges from 0
to 12. Each odorant was enclosed in melamine resin
microcapsules, which were mixed into an odorless solid
cream and then shaped like a lipstick. The examiner
painted each odor stick in a 2-cm circle on thin paraffin
paper, folded the paper in half, rubbed it to grind the
microcapsules, and then passed it to the participant.
The participant opened the paraffin paper and sniffed it.
Participants were directed to avoid eating 30 minutes
prior to the examination. The order in which the odor-
ants were presented was randomized.
Statistical Analysis
Values were expressed as mean ± standard deviation
(SD). A P value less than 0.05 was considered statisti-
cally significant. The chi-square test was used to com-
pare frequencies between groups. The Kruskal-Wallis
test was used to compare continuous variables with
skewed data distribution. Receiver operating characteris-
tic (ROC) curves were drawn and the area under the
curve (AUC) was computed to discriminate PD from
the normal control, MSA-P and PSP with 95% confi-
dence interval (95%CI), 0.95 to 1.00. The association
between MMSE and OSIT-J scores was evaluated with
Spearman’st e s t .A l la n a l y s e sw e r ep e r f o r m e du s i n gt h e
STATA 11.0 software (STATA Corporation, College
Station, TX).
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The disease duration was longer in PD than in MSA-P
and PSP, whereas the HY stage was lower in PD than in
MSA-P and PSP (Table 1). The OSIT-J scores of PD,
MSA-P, PSP, and control subjects are presented in Fig-
ure 1. Based on the score, the number of individuals
considered to have hyposmia according to the back-
ground disease was 76 in PD, 4 in MSA-P, 2 in PSP,
a n dn o n ei nt h ec o n t r o l .T h eO S I T - Js c o r ew a s4 . 4±
2.9 in patients with PD, 8.7 ± 2.2 in patients with MSA-
P, 7.6 ± 2.2 in patients with PSP, and 10.5 ± 1.3 in the
control. The mean OSIT-J score of patients with PD
was significantly lower than those with MSA-P (P <
0.0001) and control subjects (P < 0.0001), and
marginally lower than patients with PSP (P < 0.0057)
(Figure 1).
T h ea r e au n d e rt h eR O Cc u r v e( A U C )t h a td i s c r i m i -
nated PD from normal control based on the OSIT-J
score was 0.97 (95%CI, 0.95-1.00) (Figure 2A), PD from
MSA-P was 0.87 (0.80-0.95) (Figure 2B), and PD from
PSP was 0.81 (0.66-0.96) (Figure 2C). The use of an
OSIT-J scale cutoff of 7 or less, discriminated PD from
normal control with 81% sensitivity and 100% specificity
(Table 2), PD from MSA-P with 81% sensitivity and 73%
specificity, and PD from PSP with 81% sensitivity and
71% specificity. Because the control group comprised
mainly females while the PD group was mainly males,
we analyzed the data of sex-matched control-PD. The
results were similar to those of the entire group: males
only; sensitivity: 89%, specificity: 100%, females only;
sensitivity: 72%, specificity: 100%.
We also analyzed the data taking into consideration
the PD disease duration. To this effect, we included data
of PD patients with 3yashsoyo h disease (n = 36). The
clinical profile of these patients is shown in Table 1.
Table 3 shows the results of analyses of the four groups
using the data of PD patients with disease history ≤ 3
years. Like the analysis of the entire PD group, the
OSIT-J discriminated PD from normal control with 78%
sensitivity and 100% specificity (Table 3), PD from
MSA-P with 78% sensitivity and 73% specificity, and PD
from PSP with 78% sensitivity and 71% specificity.
Finally, the OSIT-J scores in patients with PD, MSA-P,
and PSP, did not correlate with age, disease duration,
and disease severity including UPDRS scores. However,
in 94 patients with PD, there was a positive correlation
between the MMSE scores and the OSIT-J scores (P =
0.027).
Discussion
The present results suggest that OSIT-J is a simple-to-
measure and sensitive marker for early-stage idiopathic
PD. This conclusion is based on the significantly lower
OSIT-J score in patients with PD than the control and
Table 1 Comparison of the four groups of subjects enrolled in the present study.
control PD PD (disease duration ≤ 3 years) MSA-P PSP p value
n 2 9 9 43 61 5 7 N / A
Age
1 (years) 66.1 ± 8.8 68.6 ± 9.7 70.1 ± 8.6 67.3 ± 9.2 70.6 ± 9.9 ns
Males/females 9/20 47/47 19/16 9/6 4/3 N/A
Disease duration
2 (years) N/A 5.1 ± 4.4 1.5 ± 1.1 2.1 ± 1.7 2.4 ± 2.0 ns
HY stage
2 N/A 2.3 ± 0.8 2.1 ± 0.7 3.0 ± 0.9* 3.1 ± 0.8* 0.0003
MMSE
1 29.6 ± 0.7 28.4 ± 1.9 28.6 ± 1.5 28.5 ± 1.9 28.6 ± 1.5 ns
UPDRS (total)
2 N/A 36.9 ± 17.2 34.7 ± 16.4 34.8 ± 15.6 48.2 ± 18.1 ns
UPDRS (part III)
2 N/A 23.1 ± 11.5 22.4 ± 11.3 22.8 ± 13.1 26.2 ± 9.8 ns
Data are mean ± SD,
1Kruskal-Wallis equality-of-populations rank test,
2Mann-Whitney U test for data of PD, MSA-P and PSP groups. N/A, not applicable; ns, not
significant; PD, Parkinson’s disease; MSA-P, parkinsonian variant of multiple system atrophy; PSP, progressive supranuclear palsy; HY stage, Hoehn Yahr stage;
MMSE, mini mental state examination; UPDRS, Unified Parkinson’s Disease Rating Scale.
Kruskal-Wallis test: P=0.0001 
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Figure 1 Box-and-whisker plots of Odor Stick Identification
Test for Japanese (OSIT-J) score in normal subjects and
patients with Parkinson’s disease (PD), parkinsonian variant of
multiple system atrophy (MSA-P), and progressive
supranuclear palsy (PSP). In these plots, lines within the boxes
represent median values; the upper and lower lines of the boxes
represent the 25th and 75th percentiles, respectively; and the upper
and lower bars outside the boxes represent the 90th and 10th
percentiles, respectively. The circles represent outlier values.
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present results are in agreement with those of previous
studies, which showed an OSIT-J score of 4.1-4.8 in
patients with PD [3,5,25]. To differentiate PD from the
controls, we used cutoff values for OSIT-J of 7, which
yielded sensitivity of 81% and specificity of 100% (Table
2). Marked olfactory dysfunction occurs in PD at the
earliest stage of the illness, affecting between 70 and
100% of patients and includes impairment in detection
threshold, identification, and discrimination [5]. SPECT
studies have shown that olfactory test scores correlated
with the levels of dopamine transporter within the stria-
tum of the brain of patients with early-stage PD [26].
On the other hand, another study showed that at 4
years from baseline, 7% of individuals with idiopathic
olfactory loss exhibited clinical symptoms of PD, and
13% of patients presented with abnormalities of the
motor system relevant to PD [2]. Since dysosmia devel-
ops before the appearance of symptoms related to
motor dysfunction, such impairment could be useful in
the detection of not only the early stages of PD but also
the premotor phase of PD [5]. Another recent study
also suggested that olfactory dysfunction in PD is asso-
ciated with both cardiac sympathetic and parasympa-
thetic dysfunction as well as with vascular sympathetic
dysfunction after adjustment for age, disease duration,
motor impairment, and dopaminergic medication. As
non-motor symptoms, olfactory and autonomic network
dysfunctions appear to be closely related in PD [25].
Since most PD patients appear to become anosmic
during later stages of the disease, it becomes clear that
the correlation between the duration of PD and olfac-
tory function is only relevant in the relatively early
stages of the disease. In turn, this also indicates that
smell sensation deficit is an early marker of PD. Based
on the neuropathological staging system for PD devel-
oped by Braak et al. [1], Lewy body formation in the
olfactory bulb and anterior olfactory nucleus precedes
the neuronal degeneration in the substantia nigra, sug-
gesting that the olfactory system may represent one of
the induction sites of the neuropathological process of
PD. This concept is, in general, in agreement with clini-
cal studies that have found olfactory dysfunction to be
independent of motor status in PD [27].
Olfaction is markedly impaired in patients with PD.
This deficit contrasts with reports of preserved or only
mildly reduced olfaction in patients with atypical parkin-
sonism. To our knowledge, the sensitivity and specificity
of olfactory function tests in the diagnosis of parkinso-
nian syndromes has not been studied in Japan. In addi-
tion, there is virtually no information on olfactory
function in patients with MSA and PSP. Using the Uni-
versity of Pennsylvania Smell Identification Test
(UPSIT) with a test score ranging from 0 to 40, Wen-
ning et al. [15] studied olfactory function in patients
with PD (n = 118), MSA (n = 29) and PSP (n = 15), as
well as 123 healthy control subjects. The UPSIT scores
showed marked impairment in the PD group, in con-
trast to the mild impairment in MSA patients and nor-
mal olfaction in PSP patients [15]. These results
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Figure 2 Receiver operating characteristic (ROC) curves. ROC curves show the relationship between sensitivity and specificity for OSIT-J score
in PD vs normal control subjects (A), in PD vs MSA-P (B), and in PD vs PSP (C).
Table 2 Discriminate analysis for Odor Stick Identification Test for Japanese (OSIT-J) in parkinsonian disorders.
OSIT-J score (≤
7
OSIT-J score (≥
8)
Sensitivity (95%
CI)
Specificity
(%)
Positive predictive
value
Negative predictive
value
PD/Control 76/0 18/29 81 (71-88) 100 (88-100) 100 (95-100) 62 (46-75)
Males 42/0 5/9 89 (77-96) 100 (66-100) 100 (92-100) 64 (35-87)
Females 34/0 13/20 72 (57-84) 100 (83-100) 100 (90-100) 61 (42-77)
PD/MSA-P 76/4 18/11 81 (71-88) 73 (45-92) 95 (88-99) 38 (21-58)
PD/PSP 76/2 18/5 81 (71-88) 71 (29-96) 97 (91-100) 78 (56-93)
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olfactory function in distinct parkinsonian syndromes
and that the UPSIT might have some value as a diag-
nostic marker. Thus, preserved or mild impairment of
olfactory function in a parkinsonian patient is more
likely to be related to atypical parkinsonism such as
MSA and PSP, whereas marked reduction in the UPSIT
s c o r ei sm o r es u g g e s t i v eo f PD. Müller et al. [28] also
found profound impairment of olfactory function in
almost all patients with PD. Consistent with the results
of Wenning et al., they also found evidence for olfactory
loss in MSA, but little or no olfactory loss in PSP
patients. Several studies have also suggested the lack of
correlation between olfactory loss with duration or
severity of the disease [27,29,30], which was confirmed
by the present study. Studies that examined the correla-
tion between pathological changes in the brain and
results of olfactory tests suggested that olfactory dys-
function in MSA could be related to glial cytoplasmic
inclusions in the olfactory bulb [31]. Another study
examined the brain of patients with PSP at postmortem
and identified neurofibrillary tangles and tau accumula-
tion in the rhinencephalon, although only three of their
patients had hyposmia [13]. The same study correlated
smell test scores with the results of bedside cognitive
and motor function tests. Their results confirmed that
the olfactory function of patients with PSP is signifi-
cantly better than that of patients with PD, but in con-
t r a s tt ot h et w op r e v i o u sp u b l i c a t i o n s ,i ta l s os h o w e d
that it was significantly reduced compared with the con-
trol after adjustment for age and gender. Our small
number of PSP also showed reduced OSIT-J score,
though it was not significantly different from the con-
trol. It is likely that the difference in the results of the
studies is due to differences in the sample size and also
certain methodological differences, such as the inclusion
of patients with PSP who presented with cognitive
impairment.
Admittedly, this study has certain limitations. First,
the clinically-based diagnosis was not confirmed patho-
logically in any of the examined subjects. Second, the
number of patients of the PSP group was too small for
meaningful conclusions. Third, patients with MSA-P
and PSP may have had undiagnosed subclinical or idio-
pathic rapid-eye-movement sleep behavior disorder
[5,32], which could affect the results. Further large scale
and longitudinal studies should be conducted to exam-
ine the diagnostic utility of OSIT-J in differentiating
patients with parkinsonian disorders.
Conclusion
The present study demonstrated marked impairment of
the smell sensation in Japanese PD patients, as tested by
a simple, inexpensive and noninvasive OSIT-J test. The
OSIT-J could be clinically useful not only for detection
of olfactory dysfunction in PD but also for differentiat-
ing PD from MSA-P and PSP.
Acknowledgements
The authors thank Mr. Youichiro Fukazawa for the clinical support. This study
was supported by Jikei University Research Fund.
Author details
1Department of Neurology, Aoto Hospital, Jikei University School of
Medicine, 6-41-2 Aoto Katsushika-ku, Tokyo 125-8506, Japan.
2Division of
Molecular Epidemiology, Jikei University School of Medicine, 3-25-8 Nishi-
shimbashi, Minato-ku, Tokyo 105-8461, Japan.
Authors’ contributions
MS participated in the conceptualization and design of the study and
drafted the manuscript. MH, MY, KK and MM conceived of the study, and
participated in its design and coordination. MU participated in interpretation
of data and performed the statistical analysis. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 May 2011 Accepted: 22 December 2011
Published: 22 December 2011
References
1. Braak H, Rub U, Gai WP, Del Tredici K: Idiopathic Parkinson’s disease:
possible routes by which vulnerable neuronal types may be subject to
neuroinvasion by an unknown pathogen. J Neural Transm 2003,
110:517-536.
2. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H:
Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov
Disord 2007, 22:839-842.
3. Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S,
Iwata M: Smell identification in Japanese Parkinson’s disease patients:
using the odor stick identification test for Japanese subjects. Intern Med
2008, 47:1887-1892.
4. Iijima M, Osawa M, Momose M, Kobayakawa T, Saito S, Iwata M,
Uchiyama S: Cardiac sympathetic degeneration correlates with olfactory
function in Parkinson’s disease. Mov Disord 2010, 25:1143-1149.
5. Miyamoto T, Miyamoto M, Iwanami M, Suzuki K, Inoue Y, Hirata K: Odor
identification test as an indicator of idiopathic REM sleep behavior
disorder. Mov Disord 2009, 24:268-273.
6. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ: Olfactory function
distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol
Neurosurg Psychiatry 2004, 75:1749-1752.
Table 3 Discriminate analysis for Odor Stick Identification Test for Japanese (OSIT-J) in parkinsonian disorders.
OSIT-J score (7) OSIT-J score (8) Sensitivity (95%CI) Specificity (%) Positive predictive value Negative predictive value
PD/Control 28/0 8/29 78 (61-90) 100 (88-100) 100 (88-100) 78 (62-90)
PD/MSA-P 28/4 8/11 78 (61-90) 73 (45-92) 88 (71-96) 58 (33-80)
PD/PSP 28/2 8/5 78 (61-90) 71 (29-96) 93 (78-99) 38 (14-68)
This analysis included data of only 36 patients with Parkinson disease who had ≤ 3-year history of PD.
Suzuki et al. BMC Neurology 2011, 11:157
http://www.biomedcentral.com/1471-2377/11/157
Page 5 of 67. Ondo WG, Lai D: Olfaction testing in patients with tremor-dominant
Parkinson’s disease: is this a distinct condition? Mov Disord 2005,
20:471-475.
8. Silveira-Moriyama L, Carvalho Mde J, Katzenschlager R, Petrie A, Ranvaud R,
Barbosa ER, Lees AJ: The use of smell identification tests in the diagnosis
of Parkinson’s disease in Brazil. Mov Disord 2008, 23:2328-2334.
9. Hughes AJ, Daniel SE, Lees AJ: Improved accuracy of clinical diagnosis of
Lewy body Parkinson’s disease. Neurology 2001, 57:1497-1499.
10. Poewe W, Wenning G: The differential diagnosis of Parkinson’s disease.
Eur J Neurol 2002, 9(Suppl 3):23-30.
11. Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R,
Conant S, Eldadah BA: Biomarkers to detect central dopamine deficiency
and distinguish Parkinson disease from multiple system atrophy.
Parkinsonism Relat Disord 2008, 14:600-607.
12. Goldstein DS, Sewell L: Olfactory dysfunction in pure autonomic failure:
Implications for the pathogenesis of Lewy body diseases. Parkinsonism
Relat Disord 2009, 15:516-520.
13. Silveira-Moriyama L, Hughes G, Church A, Ayling H, Williams DR, Petrie A,
Holton J, Revesz T, Kingsbury A, Morris HR: Hyposmia in progressive
supranuclear palsy. Mov Disord 2010, 25:570-577.
14. Silveira-Moriyama L, Mathias C, Mason L, Best C, Quinn NP, Lees AJ:
Hyposmia in pure autonomic failure. Neurology 2009, 72:1677-1681.
15. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N:
Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand
1995, 91:247-250.
16. Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D:
Olfactory testing differentiates between progressive supranuclear palsy
and idiopathic Parkinson’s disease. Neurology 1993, 43:962-965.
17. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch
Neurol 1999, 56:33-39.
18. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ,
Kaufmann H, Klockgether T, Lang AE, Lantos PL: Consensus statement on
the diagnosis of multiple system atrophy. J Neurol Sci 1999, 163:94-98.
19. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG,
Golbe LI, Grafman J, Growdon JH: Clinical research criteria for the
diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski
syndrome): report of the NINDS-SPSP international workshop. Neurology
1996, 47:1-9.
20. Fahn S, Elton RL, members Up: Unified Parkinsons Disease Rating Scale. In
Recent developments in Parkinsons diseaseFlorham Park. Volume 2. Edited by:
Fahn S, Marsden CD, Goldstein M, Calne DB. NJ: Macmillan Healthcare
Information; 1987:153-163.
21. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality.
Neurology 1967, 17:427-442.
22. Suzuki M, Hattori N, Orimo S, Fukumitsu N, Abo M, Kono Y, Sengoku R,
Kurita A, Honda H, Inoue K: Preserved myocardial [123I]
metaiodobenzylguanidine uptake in autosomal recessive juvenile
parkinsonism: first case report. Mov Disord 2005, 20:634-636.
23. Kobayashi M, Saito S, Kobayakawa T, Deguchi Y, Costanzo RM: Cross-
cultural comparison of data using the odor stick identification test for
Japanese (OSIT-J). Chem Senses 2006, 31:335-342.
24. Saito S, Ayabe-Kanamura S, Takashima Y, Gotow N, Naito N, Nozawa T,
Mise M, Deguchi Y, Kobayakawa T: Development of a smell identification
test using a novel stick-type odor presentation kit. Chem Senses 2006,
31:379-391.
25. Oka H, Toyoda C, Yogo M, Mochio S: Olfactory dysfunction and
cardiovascular dysautonomia in Parkinson’s disease. J Neurol 2010,
257:969-976.
26. Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, Stern MB,
Doty RL, Mozley PD, Wintering N: [99mTc]TRODAT-1 SPECT imaging
correlates with odor identification in early Parkinson disease. Neurology
2005, 64:1716-1720.
27. Doty RL, Deems DA, Stellar S: Olfactory dysfunction in parkinsonism: a
general deficit unrelated to neurologic signs, disease stage, or disease
duration. Neurology 1988, 38:1237-1244.
28. Müller A, Reichmann H, Livermore A, Hummel T: Olfactory function in
idiopathic Parkinson’s disease (IPD): results from cross-sectional studies
in IPD patients and long-term follow-up of de-novo IPD patients.
J Neural Transm 2002, 109:805-811.
29. Hawkes CH, Shephard BC, Daniel SE: Olfactory dysfunction in Parkinson’s
disease. J Neurol Neurosurg Psychiatry 1997, 62:436-446.
30. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, Adler C,
Gollomp S, Hurtig H: Olfactory function in Parkinson’s disease subtypes.
Neurology 1994, 44:266-268.
31. Kovacs T, Papp MI, Cairns NJ, Khan MN, Lantos PL: Olfactory bulb in
multiple system atrophy. Mov Disord 2003, 18:938-942.
32. Miyamoto T, Miyamoto M, Iwanami M, Hirata K, Kobayashi M, Nakamura M,
Inoue Y: Olfactory dysfunction in idiopathic REM sleep behavior disorder.
Sleep Med 2010, 11:458-461.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/157/prepub
doi:10.1186/1471-2377-11-157
Cite this article as: Suzuki et al.: The odor stick identification test for
Japanese differentiates Parkinson’s disease from multiple system
atrophy and progressive supra nuclear palsy. BMC Neurology 2011
11:157.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Suzuki et al. BMC Neurology 2011, 11:157
http://www.biomedcentral.com/1471-2377/11/157
Page 6 of 6